Insurance coverage for pharmacogenomic testing in the USA

Personalized Medicine

Volumn 4, Issue 4, 2007, Pages 479-487

  Williams, Marc S ^a  

^a INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

Clinical utility; Clinical validity; Coverage decision; Experimental; Investigational; Medical necessity; Oversight; Pharmacogenetics; Pharmacogenomics

Indexed keywords

AZATHIOPRINE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; MERCAPTOPURINE; NEW DRUG; SEROTONIN UPTAKE INHIBITOR; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLEEDING; BONE MARROW TOXICITY; COMMERCIAL PHENOMENA; DEPRESSION; DRUG DOSE REDUCTION; DRUG FORMULARY; DRUG METABOLISM; DRUG RESPONSE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HETEROZYGOSITY; HUMAN; HUMAN GENOME PROJECT; INDIVIDUALIZATION; LABORATORY TEST; MEDICAID; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; MEDICARE; PHARMACOGENOMICS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECOND CANCER; SINGLE DRUG DOSE; THROMBOSIS; TREATMENT PLANNING; UNITED STATES; VALIDITY;

EID: 37349054673     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.4.4.479     Document Type: Article

References (25)

1. Lander E: The nano-lectures topic: the genome. Ann. Improb. Res. 9(6), 21 (2003).
2. Alexander T: Its roundup time for the runaway regulators. Fortune 3, 126-132 (1979).
3. Furberg CD, Levin AA, Gross PA et al.: The FDA and drug safety: a proposal for sweeping changes. Arch. Intern. Med. 166(18), 1938-1942 (2006).
4. Mitka M: Report criticizes lack of FDA oversight. JAMA 296(8), 920-922 (2006).
5. Perry S, Thamer M: Health technology assessment: decentralized and fragmented in the US compared to other countries. Health Policy 40(3), 177-198 (1997). Corrected and republished in: Health Policy 42(3), 269-290 (1997).
6. Banta HD, Burns AK, Behney CJ: Policy implications of the diffusion and control of medical technology. Ann. Am. Acad. Pol. Soc. Sci. 468, 165-181 (1983).
7. Perry S: Technology assessment in health care: the U.S. perspective. Health Policy 9(3), 317-324 (1988).
8. Brown E: Minimally invasive surgery: a payer's point of view. Physician Exec. 19(3), 60-61 (1993).
9. Gudgeon JM, McClain MR, Palomaki GE, Williams MS: Rapid-ACCE: experience with a rapid and structured approach for evaluating gene-based testing. Genet. Med. 9, 473-478 (2007).
10. Cuppens H, Cassiman JJ: A quality control study of CFTR mutation screening in 40 different European laboratories. The European Concerted Action on Cystic Fibrosis. Eur. J. Hum. Genet. 3(4), 235-245 (1995).
11. Anstey A, Lennard L, Mayou SC, Kirby JD: Pancytopaenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. J. Royal Soc Med. 85, 752-756 (1992).
12. Lennard L, Welch JC, Lilleyman JS: Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br. J. Clin. Pharmacol. 44(5), 455-461 (1997).
13. McLeod HL, Krynetski EY, Relling MV, Evans WE: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14(4), 567-572 (2000).
14. Schaeffeler E, Fischer C, Brockmeier D et al.: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and indentification of novel TPMT variants. Pharmacogenetics 14, 407-417 (2004).
15. Payne K: TPMT testing in rheumatology: any better than routine monitoring? Rheumatology 46, 727-729 (2007).
16. Relling MV, Hancock ML, Rivera GK, Sandlund JT et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91(23), 2001-2008 (1999).
17. Stanulla M, Schaeffeler E, Flohr T, Cario G et al.: Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293(12), 1485-1489 (2005).
18. Sayani FA, Prosse C, Bailey RJ, Jacobs P et al.: Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can. J. Gastroenterol. 19, 147-151 (2005).
19. Anstey AV, Wakelin S, Reynolds NJ: Guidelines for prescribing azathioprine in dermatology. Br. J. Dermatol. 151, 1123-1132 (2004).
20. Carter MJ, Lobo AJ, Travis SP: Guidelines for the management of inflammatory bowel disease in adults. Gut53(Suppl. 5), V1-V16 (2004).
21. Marshall E.: Preventing toxicity with a gene test. Science 302, 588-590 (2003).
22. Marchant GE, Milligan RJ, Wilhelmi B: Legal pressures and incentives for personalized medicine. Personal Med. 3(4), 391-397 (2006).
23. Fihn SD, Callahan CM, Martin DC, McDonell MB et al.: The risk and severity of bleeding complications in elderly patients treated with warfarin. Ann. Intern. Med. 124, 970-979 (1996).
24. Krynetskiy E, McDonnell P: Building individualized medicine: prevention of adverse reactions to warfarin therapy. J. Pharmacol. Exp. Ther. (Epub ahead of print) (2007).
25. Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard Warfarin dosing in patients initiating oral anticoagulation. Circulation (Epub ahead of print) (2007).